1. Introduction {#sec1}
===============

The most common cause of isolated acquired aortic stenosis (AS) in both developed and developing countries is age-related degeneration of the aortic valve. Prevalence of isolated AS was found to be as high as 7.3% in an Indian hospital-based echocardiographic survey, with most of the patients being aged more than 60 years.[@bib1] Studies from Western data have revealed that in patients aged over 75 years overall prevalence of AS is 12.4% and that of severe symptomatic AS is 3.4%.[@bib2] These patients have a survival rate as low as 15--50% at 5 years without aortic valve replacement.[@bib3] By extrapolating Western prevalence data to the Indian population, it is estimated that nearly 300,000 patients with AS are likely to be eligible for aortic valve replacement. Until recent times, the standard of care therapy was surgical aortic valve replacement (SAVR) for symptomatic severe AS. It has been observed that SAVR has good outcomes across broad populations with low complication rates. However, it has been reported that up to 30% of patients with severe symptomatic AS do not undergo SAVR, because of reasons such as advanced age, associated comorbid conditions, previous surgery, inoperability or high risk, and unwillingness to undergo open heart surgery. Transcatheter aortic valve replacement (TAVR), a percutaneous procedure, has transformed care of high risk and inoperable AS. Since the introduction of TAVR, there has been continuous innovation in the technology and improvement in patient selection and implantation techniques. SAVR is now challenged by TAVR for severe AS today, with \>3,00,000 procedures being performed in more than 1000 global centers and a substantial amount of emerging data. TAVR was initially shown to be efficacious and safe in inoperable patients, also known to be at extreme risk for surgery.[@bib4] In these patients, TAVR reduced overall mortality as compared with medical therapy or balloon valvuloplasty. Also, both balloon-expandable and self-expandable TAVR have demonstrated noninferiority to surgery across high-risk patient populations.[@bib5] Owing to proven advantage of TAVR, the US Food and Drug Administration subsequently granted marketing approval, and now, it has become the standard of care in high-risk patients. As per the Placement of AoRTic TraNscathetER Valve Trial - IIA (PARTNER-IIA) trial[@bib6] and Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients - (SURTAVI) trial,[@bib7] TAVR was noninferior to SAVR in intermediate-risk groups with respect to primary clinical outcomes, expanding the indication to intermediate-risk patients. Despite the increasing popularity of TAVR, only about 10,000 TAVR cases have been performed in Asia to date. The procedure is still in its nascent stage in India with very few centers offering this state-of-art technique. Here, we present the early results of our TAVR experience in our center

2. Materials and methods {#sec2}
========================

2.1. Patient inclusion and preprocedure evaluation {#sec2.1}
--------------------------------------------------

A total of 49 patients with severe symptomatic AS were evaluated and found to be at high risk for SAVR and were referred to our center for TAVR, during the period from November 2015 to February 2018. Baseline data of all the patients were recorded. Parameters such as demographic details, history of present illness, Society of Thoracic Surgeons (STS) score, and European System for Cardiac Operative Risk Evaluation (EURO) scores were recorded. Baseline echocardiography was performed. Patients were selected for TAVR based on the risk assessment and after a detailed discussion by the heart team that included a cardiologist, cardiothoracic surgeon, and cardiac anesthetist. The risk assessment not only involves STS/EURO score but also other high risks features such as frailty, chest deformities, and oxygen-dependent respiratory failure. Computed tomography (CT) was performed in all the patients, and information about annulus size, optimal angiographic projection for device implantation, and other information such as sinus width, leaflet size, and calcification were collected. Echo parameters were repeated postoperatively, at the time of discharge, after 1 month of the procedure, and 6 and 12 months after the procedure along with assessment of comorbidities. If the CT Coronaries coronary angiography was normal or showed insignificant disease, regular catheter coronary angiography was avoided. Patients who had significant left main disease, proximal left anterior descending artery (LAD) stenosis, or acute coronary syndrome were considered for percutaneous coronary intervention (PCI) before TAVR. However, patients having non-LAD single disease were left with medical management.

2.2. TAVR procedure protocol {#sec2.2}
----------------------------

At our center, TAVR is performed in a regular catheterization laboratory which has adequate space to accommodate device preparation, echocardiographic equipment, anesthesia equipment, and other surgical instruments in a sterile environment. The preferred access site for the procedure was through the transfemoral route whenever feasible. The procedure was performed under conscious sedation or general anesthesia, depending on compromised hemodynamics or patient preference. Conscious sedation offers advantage of better hemodynamic status, shorter procedural duration, and shorter length of intensive care unit stay. Transesophageal echocardiogram (TEE) was planned for selected cases. Intraprocedural TEE was not performed routinely as it usually requires general anesthesia. Also, the probe used for TEE may partially obstruct the fluoroscopic view, necessitating multiple retractions and advancements during the procedure. However, it was considered in patients having severe native valve calcifications and in patients who had previous mitral prosthesis. Before the procedure, a temporary pacing catheter (a balloon-tipped lead) was positioned in the right ventricle via the right jugular or femoral venous route. Both the groins were used for vascular access: on one side, a 6F or 7F access for a pigtail catheter and on the other side, preinsertion of two proglide and an initial 9F sheath, which was later upgraded to the larger TAVR introducer sheath. Aortography was performed, and native aortic valve was crossed by a straight guidewire followed by pressure gradient measurement. An undersized balloon was used for balloon dilatation, and simultaneous aortogram was performed during a brief period of rapid ventricular pacing. During balloon valvuloplasty, the risk of coronary occlusion was assessed. Balloon-expandable valves were deployed under rapid ventricular pacing, whereas the self-expanding valve was slowly released usually without pacing as per protocol. Subsequently, aortic valve gradients were again measured along with angiographic and echocardiographic assessments for paravalvular leaks (PVLs). In case of significant PVL, postdilatation was performed. After the completion of the procedure, catheters and guidewires were withdrawn, and hemostasis was achieved.

3. Results {#sec3}
==========

3.1. Baseline data {#sec3.1}
------------------

Of the 49 patients with severe symptomatic AS who were evaluated by us, 24 patients did not undergo the procedure ([Table 1](#tbl1){ref-type="table"}). Seventeen patients did not undergo due to monetary constraints, 2 patients had sudden cardiac death during the evaluation period, 1 patient had pseudosevere AS, 3 patients with severe coronary artery disease required cardiac bypass graft (CABG), and one was post-SAVR patient having severe concentric hypertrophy with severe left ventricular outflow tract gradient. Of the 25 patients who underwent TAVR, 17 (68%) were males and 8 (32%) were females. The mean age of the patients was 72.0 ± 8.1 years. Diabetes mellitus was found in 16 of 25 (64%), hypertension in 16 of 25 (64%), chronic kidney disease in 10 of 25 (40%), moderate-to-severe chronic obstructive pulmonary disease in 10 of 25 (40%) patients. At baseline, most of them (88%) had New York Heart Association (NYHA) class III or IV dyspnea. Four patients had a history of syncope while none had a history of angina. All patients underwent CT coronary angiogram. Conventional coronary angiogram was performed in 13 patients, who had coronary artery disease revealed by CT. One patient had left main disease, and 8 patients had LAD disease. Four patients underwent PCI of LAD before TAVR. Three were post-CABG patients, and 2 were post-mitral valve replacement patients. Two patients had significant peripheral vascular disease of right iliac and femoral arteries, which required the use of the left femoral route for valve introduction. Three had chronic liver disease. Baseline mean STS score was 13.8 ± 10.2, while the mean baseline EURO score was 17.54 ± 4.6. Baseline ejection fraction (EF) was found to be 50.3 ± 14.8, with 7 patients having severe left ventricular dysfunction. Baseline mean aortic valve (AV) gradient was 55.8 ± 24.7 mmHg. Five patients had low-flow, low-gradient AS. Dobutamine stress echo diagnosed 4 patients with severe AS and 1 with pseudosevere AS, who was excluded.Table 1Baseline data.Table 1Gender distributionMales: 17/25 (68%)\
Females: 8/25 (32%)Mean age72 ± 8.1 yearsBaseline anginaNilBaseline dyspneaGrade II: 2 (8%)Grade III: 8 (32%)Grade IV: 15 (60%)Comorbid conditionsDiabetes mellitus: 16/25 (64%)Hypertension: 16/25 (64%)Chronic kidney disease: 10/25 (40%)Coronary artery disease: 13/25 (52%)COPD: 10/25 (40%)PVD: 2/25 (8%)CLD: 3/25 (12%)STS score13.8 ± 10.2EURO score17.54 ± 4.6PAHNil: 12Mild: 4Moderate: 5Severe: 4Aortic regurgitationNil: 4Mild: 12Moderate: 9Severe: NilEjection fraction\<35%: 735--55%: 8\>55%: 10Mean EF50.3 ± 14.8Mean aortic valve gradient55.8 ± 24.7  mmHgMean annulus perimeter72.6 ± 12.4 mmMean annulus area (perimeter derived)410.1 ± 121.8 mmMean annulus diameter (perimeter derived)25.4 ± 8.2 mmMean annulus diameter (area based)22.1 ± 5.2 mmPrevious historyCABG: 3MVR: 2CVA: Nil[^1][^2]

3.2. Hospital stay and discharge {#sec3.2}
--------------------------------

Procedural details are given in [Table 2](#tbl2){ref-type="table"}. There was one procedure-related death, where the patient with baseline severe left ventricular dysfunction developed asystole post-valve deployment with rapid pacing, he was revived and placed on *extracorporeal membrane oxygenation* support, but died 2 days later. One patient required urgent surgery for contained annular rupture, and one patient underwent vascular repair for femoral artery occlusion. Two patients required peripheral stent placement, and one required balloon dilatation for femoral artery occlusion. Four patients developed complete heart block (two in self-expandable valve and two in balloon expandable valve) requiring permanent pacemaker implantation. Two patients had acute kidney injury not requiring dialysis.Table 2Procedural details.Table 2AnesthesiaGeneral: 15 (60%)\
Conscious sedation: 10(40%)Access routeFemoral: 25 (100%)Use of transesophageal16/25 (64%)EchocardiogramLV wireAmplatz super/extrastiff wire: 17/25 (64%),Confida wire: 6/25 (24%),Lunderquist wire: 2/25 (8%)Preprocedure vascular cutdownNilPreprocedure proglide25/25 (100%)PredilatationEvolut R/Core valve: 5Sapien 3: 5Valve typeEvolut R: 15 (60%)SAPIEN 3: 7 (28%)Core valve: 2 (8%)Balloon-expandable study valve: 1 (4%)Valve size23 mm: 6/25 patients (24%)26 mm: 11/25 patients (44%)29 mm: 8/25 patients (32%)Paravalvular leakSevere PVL: NilModerate PVL: 3 (12%)Mild PVL: 11 (44%)No PVL: 11 (44%)Postdilatation required3 (12%)Immediate postprocedure mean LV ejection fraction55.4 ± 9.4%Immediate postprocedure mean aortic valve gradient8.5 ± 4.9 mmHgProcedural success25/25 (100%)[^3][^4]

At discharge, majority of the patients were in NYHA class I to II status (80%), while five patients had class III dyspnea ([Fig. 1](#fig1){ref-type="fig"}). None of the patients had angina at discharge. Mean left ventricular ejection fraction (LVEF) at discharge was 55.4 ± 9.4%, while mean AV gradient was 8.5 ± 4.9 mmHg. Mild PVL was seen in 11 patients and moderate PVL in 3 patients. None had severe PVL. All patients were on dual antiplatelet therapy at discharge, except 3 who were on oral anticoagulation for atrial fibrillation.Fig. 1Dyspnea grade during follow-up period as compared with the baseline. Postprocedure period there was significant improvement in dyspnea, which maintained on 1-year follow-up.Fig. 1

3.3. Follow-up {#sec3.3}
--------------

1 month: One-month follow-up was completed in all 24 patients ([Table 3](#tbl3){ref-type="table"}). None of the patients had any major adverse cardiac events (MACEs). All patients were in NYHA class I to II status. Mean LVEF was 55.4 ± 9.6%, while mean AV gradient was 8.8 ± 3.6 mmHg. Mild PVL was seen in 7 patients.Table 3In-hospital, 1-month, 6-month, 1-year, and 2-year follow-up results.Table 3In-hospital complications and mortality Coronary occlusionNil Annular rupture1/25 (4%) Minor vascular complications4/25 (16%) Femoral occlusion4/25 (16%) Femoral artery stenting2/25 (8%) Femoral balloon dilatation1/25 (4%) Groin hematoma1/25 (4%) Complication requiring surgical intervention2/25 (8%) Conduction abnormality4/25 (16%) Pacemaker implantation4/25 (16%) Acute kidney injury (recovered)2/25 Acute kidney injury requiring dialysisNil Stroke or transient ischemic attackNil Atrial fibrillation3/25 (12%) Mortality1/25 (4%) Median length of stay (LoS)6 days Prolonged hospital stay more than 10 days2/25 (8%)30-day MACCENil (*n* = 24)6-month MACCENil (*n* = 19)1-year MACCENil (*n* = 12)2-year MACCENil (*n* = 3)All-cause 1-year mortality (including cardiac and noncardiac causes)2/25 (8%)[^5]6 months: Six-month follow-up was completed in 19 patients. There were no MACEs during the 6-month follow-up. All the patients were in class I to II status. All except one patient showed significant improvement in EF with mean LVEF of 56 ± 8.9%, while the mean AV gradient was 8.3 ± 2.8 mmHg. Mild PVL was seen in 3 patients.12 months: One-year follow-up was completed in 12 (50%) patients. The overall all-cause mortality during 1-year follow-up was 8%. There was 1 unrelated noncardiac cause of death due to dengue shock syndrome. All the patients were in NYHA class I to II status. Mean LVEF was 55 ± 9%, while the mean gradient AV was 8 ± 3.5 mmHg. None of the patients had PVL.24 months: Two-year follow-up was completed in 3 patients. All 3 patients are in NYHA class I-II status with no morbidity or mortality. All had normal LV function with no significant increase in the mean gradient.

4. Discussion {#sec4}
=============

TAVR is a novel innovation and is a dawn of a new era in the field of minimal invasive procedure in the treatment of severe symptomatic AS. The experience in India about the procedure is limited with a very few centers which are equipped with expertise and personnel to carry out the TAVR procedure. The present study included 25 patients suffering from AS who underwent TAVR. Baseline characteristics showed that majority of patients were males with most having age more than 70 years and multiple comorbid conditions. Procedural success was (100%) with no major intraoperative and postoperative complications in most of the patients. The vascular complications were slightly higher in our series (16%); advancing a cross-over wire from the contralateral femoral artery and using a routine balloon inflation at the time of Perclose suture deployment have shown to significantly reduce the vascular complications to \<3--4% in the transcatheter valve therapy registry. At baseline, 92% patients had severe dyspnea which showed significant improvement at discharge with 80% in class I to II status and remained so in subsequent follow ups ([Fig. 1](#fig1){ref-type="fig"}). LVEF and mean flow gradient showed significant improvement, and these improvements were maintained till the end of 1-year follow-up ([Fig. 3](#fig3){ref-type="fig"}, [Fig. 4](#fig4){ref-type="fig"}). Mild PVL was seen in 44% and moderate PVL in 12% of the patients at discharge. All PVL disappeared at the end of first year ([Fig. 2](#fig2){ref-type="fig"}). Study results varied based on the type of valve implanted with the self-expanding valve showing no effect of PVL on mortality, with nearly 80% of severe PVL reducing to mild or disappearing by 1 year.[@bib8] However, studies with balloon-expandable valves showing a significant increase in mortality on follow-up if the paravalvular regurgitation is more than mild.[@bib6] Post-TAVR conduction abnormalities resulting in permanent pacemaker implantation (PPI) vary from 4 to 6.0% for the Edwards SAPIEN[@bib4], [@bib5], [@bib6] to about 19--22% for the Medtronic Core Valve.[@bib6], [@bib7] In our series, overall 16% of the patients required permanent pacemaker. However, the mortality rates at 2-year follow-up are not different between patients requiring PPI and patients not requiring PPI.[@bib7] Pacemaker requirement and residual PVLs after the procedure are higher than the reported in the current era and may be related to the initial experience of the performing team. In our study group, in-hospital and 1-month mortality was 4%, and one-year all-cause mortality was 8%. The initial studies with balloon-expandable valves conducted on high-risk patients showed a 1-month mortality of 3--5% at 1 month and 24--30% at 1 year.[@bib4], [@bib5] Study using self-expanding valves on high-risk patients had shown 1-year mortality of 14%.[@bib8] In the intermediate-risk group, the 1-year mortality was 14% with balloon-expandable valves and 8.8% with the self-expanding valve.[@bib6], [@bib7] The risk of stroke was about 2--4% in trials using both balloon- and self-expanding valves.[@bib4], [@bib5], [@bib6], [@bib7] Also, data from the Western countries have limited information on the outcomes of TAVR performed on bicuspid aortic valves. In our series, nearly half (48%) of our TAVR cases had bicuspid aortic valves; however, because the overall numbers were less, there was no comparison. Our average length of stay had been 6 days, and two of our cases with SAPIEN 3 valve replacement were discharged the next day. TAVR is a less invasive option, provides early ambulation, has fewer complications, improves the quality of life, and results in durable outcomes. So far, the long-term data with TAVR are encouraging for patients completing the 5-year follow-up and beyond, with the risk of death similar to SAVR and no need for re-replacement of the valve.[@bib9] In India, in the current scenario, TAVR can be safely considered as the first-line therapy for patients with severe AS who are at high risk for surgery.Fig. 2Paravalvular leak (PVL) grade during follow-up period as compared with the baseline. Immediate postprocedure moderate PVL was seen in 3 patients, and 11 patients had mild PVL. All PVL disappeared by the end of 1 year.Fig. 2Fig. 3Aortic valve (AV) mean gradient ± 2 SD, at the baseline and during 1-year follow-up. Baseline mean gradient was 55.8 ± 24.7  mmHg. Immediate postprocedure mean gradient was 8.5 ± 4.9  mmHg. One-month mean gradient was 8.8 ± 3.6  mmHg. Six-month mean gradient was 8.3 ± 2.8  mmHg. One-year mean gradient was 8 ± 3.5  mmHg. SD, standard deviation.Fig. 3Fig. 4Mean ejection fraction (EF) ± 2 SD, at the baseline and during 1-year follow-up. Baseline mean EF was 50.3 ± 14.8%. Immediate postprocedure mean EF was 55.4 ± 9.6%. The 1-month, 6-month, and 1-year mean EF are almost equal. SD, standard deviation.Fig. 4

4.1. Economic challenges in India {#sec4.1}
---------------------------------

In 2016, mean procedure costs in the United States were USD 69,592 for TAVR and USD 58,332 for SAVR.[@bib10] When compared with the cost in the United States, the cost of TAVR in India is almost half (USD 34,900), still TAVR costs roughly 6 times that of conventional SAVR, of which two-third of the costs are contributed by valve costs alone. In our series, 40% of patients did not undergo TAVR because of cost constrains. At current costs, it is certainly a mammoth task for our government to support such an expensive program for the entire country. This sets an uphill task for the clinicians to get the financing models for the patients to undergo TAVR as most of the insurance agencies in the country reimburse for the conventional procedures, and the balance pie has to be the out-of-pocket expenditure. An important concern has been the elderly subsets of patients wherein the TAVR costs and managing the comorbidities are high, which has been a matter of due diligence and a critical decision-making from the patient families to buy-in for TAVR. Technological advancements and procedural simplification, availability of locally manufactured devices with an advent of indigenous native Indian valves, and increase in volume of cases performed may ultimately reduce the overall cost of a TAVR procedure.

4.2. Regulatory challenges for TAVR program {#sec4.2}
-------------------------------------------

Regulatory body approval was one of the major hurdles in India till early 2016, wherein the valves had to be imported under patient individual license. Ever growing data from TAVR trials on the benefits and effectiveness of the procedure resulted in the fast tracked approvals of the two major TAVR valves by the Indian regulatory authority by 2016.

4.3. Organizing heart team and training challenges for TAVR program {#sec4.3}
-------------------------------------------------------------------

A successful procedure relies on multiple factors such as appropriate patient selection involving a multidisciplinary "heart team," meticulous planning, and maintaining high standards of care during and after the procedure. All patients were assessed and thoroughly investigated by blood tests, echocardiography, and CT imaging before discussion in the heart team conference. Our heart team includes interventional cardiologists, imaging specialists, heart surgeons, and cardiac anesthesiologists. Neurologists are involved in the initial heart team discussion, if the patient had a history of previous stroke or any neurological disorder requiring assessment. Asian/Indian patients have several unique anatomical characteristics. Iliofemoral vessel diameter is likely to be smaller.[@bib11] Body size and aortic valve annulus tends to be smaller, predisposing to higher risk of annular rupture, residual gradients, and vascular complications.[@bib12], [@bib13] Third, we have seen more bicuspid valves in India, and they are associated with unique challenges. The companies involved in the manufacture of prostheses have an organized training and proctoring program for TAVI teams, which is usually provided at one of the high-volume centers around the world. After a certain adequate number of proctored cases, we started performing TAVI independently without supervision.

4.4. Limitations of the study {#sec4.4}
-----------------------------

The main limitation was the small sample size and also 1-year follow-up was completed only in 50% of the patients.

5. Conclusion {#sec5}
=============

TAVR is a good alternative for symptomatic severe AS for high and intermediate surgical risk cases. TAVR in India has just commenced, and quaternary care hospitals with their strong heart team and TAVR program have embarked on these newer procedures. As data from large-scale studies become available, TAVR may soon replace the conventional SAVR for high-risk AVR cases in the next few years once costs are scaled down from 50% to 70% of the current scenario. During initial years of implementation of a nationwide TAVI program, it may be prudent to collate the outcomes of large volume centers performing TAVR and focus on creating TAVR centers of excellence. With the burgeoning growth of TAVR in India, scientific collaborations with different advocacy groups should be created for developing a successful hub and spoke model. However, financial implications, nonavailability of expertise, and lack of awareness remain the major challenges in India.
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[^1]: Data are presented as mean ± SD or as number and percentage.

[^2]: CABG, cardiac bypass graft; COPD, chronic obstructive pulmonary disease; CLD, chronic liver disease; CVA, cerebrovascular accident; EF, ejection fraction; EURO, European System for Cardiac Operative Risk Evaluation; MVR, mitral valve replacement; PAH, pulmonary arterial hypertension; PVD, peripheral vascular disease; STS, Society of Thoracic Surgeons.

[^3]: Data are presented as mean ± SD or as number and percentage.

[^4]: LV, left ventricle; PVL, paravalvular leak.

[^5]: MACCEs, major adverse cardiac and cerebrovascular events.
